斑秃调查分析提示改善患者报告结局的阈值
该研究在度普利尤单抗治疗斑秃的随机对照试验中分析两种斑秃生活质量问卷的效用。AASIS与基线SALT评分及治疗反应相关,AA-QLI与病情严重程度无关。治疗后SALT≤20分与患者报告结局改善相关,AASIS优于AA-QLI。
要点
- AASIS与基线SALT评分和治疗反应相关,AA-QLI与病情严重程度无关。
- 瘙痒与血清IgE水平在两种问卷中均强相关。
- 治疗后SALT≤20分与患者报告结局改善相关,可作为未来临床试验的临床终点。
核心结论
- AASIS在评估患者报告结局方面优于AA-QLI。
- 治疗后SALT≤20分应被视为有意义的治疗结局阈值,并作为未来斑秃临床试验的临床终点。
研究设计与样本
- 在近期一项测试度普利尤单抗治疗斑秃的随机对照试验中,患者接受了斑秃生活质量指数(AA-QLI)和斑秃症状影响量表(AASIS)调查,并对问卷的效用进行了深入分析。
主要发现
- AASIS与基线严重度脱发工具(SALT)评分及治疗反应相关,而AA-QLI在治疗前后均与斑秃严重程度无关。
- 瘙痒在两种问卷中均与血清IgE水平强相关。
- 采用多种方法估算治疗后斑秃对生活质量影响减小的判别阈值,发现治疗后SALT评分≤20分与患者报告结局改善相关,包括斑秃相关症状以及日常活动/感受领域中的条目如「感到悲伤」和「感到焦虑或担忧」。
关键数值与推荐
- 治疗后SALT评分≤20分与患者报告结局改善相关,包括斑秃相关症状和日常活动/感受领域条目。
临床怎么用
- 作者认为,治疗后SALT≤20分应被视为有意义的治疗结局阈值,并作为未来斑秃临床试验的临床终点。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although alopecia areata (AA) greatly impacts patients' quality of life (QoL), there is no adequate validation of AA-targeted QoL surveys in clinical trials, hindering sufficient representation of patient-reported outcomes. OBJECTIVES: Better understanding of patient-reported outcomes may guide treatment goals and future clinical trials. METHODS: In a recent randomized controlled trial testing dupilumab in AA, patients were administered the Alopecia Areata Quality of Life Index (AA-QLI) and the Alopecia Areata Symptom Impact Scale (AASIS) surveys, specifically evaluating QoL in patients with AA. An in-depth analysis was performed to assess the utility of these questionnaires in this patient population, both at baseline and after treatment, and to determine a threshold for improved patient-reported outcomes. RESULTS: While AASIS correlated with baseline Severity of Alopecia Tool (SALT) scores and with therapeutic response, AA-QLI showed no correlation with AA severity before or after treatment. Itch strongly correlated with serum IgE levels across both surveys. Using various approaches to estimate a discriminative threshold for decreased impact of AA on QoL (by AASIS) following treatment, a SALT score of 20 points or less post-treatment was associated with improved patient-reported outcomes, including both AA-related symptoms and items within the daily activities/feelings domain such as 'feeling sad' and 'feeling anxious or worry'. CONCLUSIONS: AASIS is better than AA-QLI to assess patient-reported outcomes. SALT ≤ 20 following treatment should be considered as a threshold for meaningful therapeutic outcome and as a clinical endpoint in future clinical trials for AA. What is already known about this topic? Alopecia areata greatly compromises quality of life, and affected patients have increased prevalences of depression, anxiety and social phobia. Despite the significant negative impact of the disease on patients' wellbeing, validation of targeted questionnaires in alopecia areata is lacking, and a therapeutic response threshold for improved patient-reported outcomes is unknown. What does this study add? This study investigated the utility of two different alopecia areata-targeted questionnaires - Alopecia Areata Quality of Life Index and Alopecia Areata Symptom Impact Scale (AASIS) - in a clinical trial setting. AASIS was found to correlate strongly with alopecia areata severity and clinical response. What are the clinical implications of this work? Patients with ≤ 20% scalp hair loss after treatment reported improvement in multiple quality-of-life items, suggesting this as a meaningful therapeutic outcome that may guide clinicians and improve the development of future clinical trials.
引用
- Renert-Yuval Y, Correa da Rosa J, Garcet S, et al. Analysis of alopecia areata surveys suggests a threshold for improved patient-reported outcomes. Br J Dermatol. 2022. PMID: 35656793. doi:10.1111/bjd.21696
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。